Accessibility Menu
Cns Pharmaceuticals logo

Cns Pharmaceuticals

(NASDAQ) CNSP

Current Price$4.75
Market Cap$6.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-100%
5 Year-100%
1 Year-54%
1 Month+2%
Cns Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 4.742026-07-16
Cns Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-10.9%USD 5.322026-07-09
1 month+2.38%USD 4.632026-06-16
3 month+86.61%USD 2.542026-04-17
Year to date-9.71%USD 5.252025-12-31
1 year-54.24%USD 10.362025-07-16
3 year-99.99%USD 64,200.002023-07-17
5 year-100%USD 1,638,000.002021-07-16
Since inception-100%USD 4,113,041.132019-11-08

Cns Pharmaceuticals Financials at a Glance

Market Cap

$6.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$16.49M

EPS (TTM)

-$29.63

P/E Ratio

-0.16

Dividend

$0.00

Beta (Volatility)

0.67 (Low)

Price

$4.75

Volume

80

Open

$4.81

Previous Close

$4.75

Daily Range

$4.75 - $4.81

52-Week Range

$1.90 - $10.59

Estimated Earnings Date

Aug 17, 2026

CNSP News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cns Pharmaceuticals

CNS Pharmaceuticals develops drugs for brain and nervous system cancers. Its main products aim to help patients with aggressive brain tumors. The company focuses on treatments for diseases with few existing options.

Lab Coats and Pipettes: Products and Services

  • Berubicin: Experimental chemotherapy for glioblastoma, a fast-growing brain tumor; no revenue generated.
  • TPI 287: Synthetic drug designed to cross the blood-brain barrier for brain and other cancers; no revenue generated.
  • Pipeline Expansion: Actively seeking new neurology and oncology drug candidates through licensing or acquisition.
  • Out-Licensing: Exploring partnerships to license out legacy drug candidates to other companies.

Plot Twists: Growth and Expansion

  • In 2026, shifted strategy from single brain cancer focus to broader neurology and oncology pipeline.
  • Signed licensing agreements with Houston Pharmaceuticals and Reata Pharmaceuticals; Berubicin was originally discovered at The University of Texas M.D. Anderson Cancer Center.
  • Entered a development agreement with WPD Pharmaceuticals and a sublicense agreement with Animal Life Sciences.
  • Appointed new executive team in early 2026 to drive asset acquisition and business development.

Why CNS Pharmaceuticals Stands Out (Without the Lab Goggles)

The company’s pivot in 2026 broadened its focus to more diseases, aiming for a diverse drug pipeline. It relies on partnerships and licensing to access new treatments. CNS Pharmaceuticals operates with a small team and outsources much of its research work.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Net loss was $3 million in Q3 2025, improving 42.2% from Q3 2024.
  • Cash used in operations was $2 million in Q3 2025, improving 68% from Q3 2024.
  • Cash position was $7.2 million as of December 31, 2025.

Bottom Line

CNS Pharmaceuticals is evolving from a single-drug focus to a broader neurology and oncology strategy. The company faces ongoing losses and depends on new partnerships and funding to continue operations.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

8

CEO

Rami Levin, MBA

Website

www.cnspharma.com

Headquarters

Houston, TX 77027, US

CNSP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-238.69%

Return on Capital

-329.54%

Return on Assets

-354.30%

Earnings Yield

-6.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.46M

Volume

80

Avg. Volume

1.43M

Financials (TTM)

Gross Profit

-$768.00

Operating Income

-$16.62M

EBITDA

-$16.47M

Operating Cash Flow

-$15.22M

Capital Expenditure

-$24.36K

Free Cash Flow

-$15.24M

Cash & ST Invst.

$2.95M

Total Debt

$232.35K

Cns Pharmaceuticals Performance Analysis

Cns Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Cns Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Cns Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -336,499.50-32.0%
20232023-12-31USD -150,114.30-55.4%
20242024-12-31USD -466.44-99.7%
20252025-12-31USD -35.75-92.3%
Cns Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3066.1%
Q32025-09-3010.3%
Q42025-12-31-76.2%
Q12026-03-3128.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$1.87K

-69.8%

Gross Margin

0.00%

N/A

Market Cap

$6.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$865.91K

N/A

Employees

8

N/A

Net Income

-$4.94M

-14.8%

EBITDA

-$4.93M

-14.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.95M

-77.4%

Total Debt

$232.35K

+10.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$232.35K

+10.3%

Return on Assets

-3.54%

N/A

Return on Invested Capital

-235.12%

N/A

Free Cash Flow

-$4.65M

-43.6%

Operating Cash Flow

-$4.65M

-43.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SILOSilo Pharma, Inc.
$4.78-1.95%
SNGXSoligenix, Inc.
$0.36-3.31%
KTTAPasithea Therapeutics Corp.
$0.46-4.35%
ENSCEnsysce Biosciences, Inc.
$0.28-4.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$207.33-0.02%
AAPLApple
$333.13+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.51-0.12%
NUNu Holdings
$13.78-0.01%

Questions About CNSP

What is the current price of Cns Pharmaceuticals?

Cns Pharmaceuticals is trading at $4.75 per share.

What is the 52-week range for Cns Pharmaceuticals?

Over the past 52 weeks, Cns Pharmaceuticals has traded between $1.90 and $10.59.

How much debt does Cns Pharmaceuticals have?

As of the most recent reporting period, Cns Pharmaceuticals reported total debt of $232.35K.

How much cash does Cns Pharmaceuticals have on hand?

Cns Pharmaceuticals reported $2.95M in cash and cash equivalents in its most recent financial results.

What is Cns Pharmaceuticals’s dividend yield?

Cns Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services